{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-022484","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2024-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.963813+00:00","generated_at":"2026-05-31T22:00:12.348724+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Vistagen expands PH80 global patent portfolio with new migraine treatment patents in four countries","bullets":["New patents for PH80 migraine treatment issued/allowed in Australia, Hong Kong, Japan, and Mexico.","All new patents expected to be in effect until 2040, subject to possible term extensions.","PH80 is a non-systemic, hormone-free investigational pherine nasal spray for menopausal hot flashes and other conditions.","Patents complement previously granted U.S. Patent No. 11,419,881 and EPO Patent No. 3955933 for migraine."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-022484","json":"https://secwatch.observer/filing/0001437749-24-022484.json","markdown":"https://secwatch.observer/filing/0001437749-24-022484.md","text":"https://secwatch.observer/filing/0001437749-24-022484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000143774924022484/0001437749-24-022484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000143774924022484/vtgn20240710_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:00:12.348724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}